CPE, China Structural Reform Fund lead $100m round in biotech firm TransThera

Photo by Louis Reed on Unsplash

Chinese clinical-stage biotech firm TransThera Biosciences has raked in about $100 million in a Series D round of financing to further the development of its pipeline products in the global market.

The Series D round was jointly led by CITIC’s alternative asset management unit CPE and China Structural Reform Fund. Hong Kong-listed financial institution China Renaissance, the exclusive financial advisor to the deal, announced the development in a WeChat post on Friday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter